A phase I, multi-dose study of SGN-40 (anti-huCD40 mAb) in patients with non-Hodgkin's lymphoma

Trial Profile

A phase I, multi-dose study of SGN-40 (anti-huCD40 mAb) in patients with non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Dacetuzumab (Primary)
  • Indications Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 09 Oct 2008 Actual patient number is 50; study end date changed from July to March 2007, as reported by ClinicalTrials.gov.
    • 09 Oct 2008 Genentech reported as a trial Sponsor by ClinicalTrials.gov.
    • 06 Jun 2008 Final results were reported during an oral presentation at the International Conference on Malignant Lymphoma (ICML).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top